Find Clinical Trial

Efficacy and safety of agomelatine (25-50 mg/day) for 12 weeks in patients with Generalized Anxiety Disorder: a randomised controlled trial

← Back
Study Phase

Phase 3

Therapeutic Area

Neuropsychiatric Diseases

IndicationGeneralised Anxiety Disorder
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device


Active Substance CodeS020098
Protocol CodeCL3-20098-078

Documents and links

Results summary READ MORE


"Picarel F; Zhao JP; Sulaiman AH; Huang YS; Sisrurapanont M; Wei KC; Albarran Severo C; Olivier V; De Bodinat C Eur Psychiatry. 2018; 48(Suppl.):S145-S146"

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.

© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.